News – Page 897 – Endpoints News

Editas and Celgene sub Juno are tackling hottest immunotherapy cells

6 years ago

Amgen axes 149 of its staff in Cambridge office; Evotec, MilliporeSigma enter research pact

6 years ago

Flagship woos Novartis top dealmaker Prakash Raman in move to get the BD ball rolling early

6 years ago

Celgene execs shell out $92M cash for a pair of R&D deals that will fit perfectly in their new home at Bristol-Myers

6 years ago

Reata's bardoxolone offers promise in patients with rare kidney disorder

6 years ago

FDA Vascepa review spotlights new safety signals, possible mineral oil spoiler as Amarin hunts a blockbuster approval

6 years ago

Kadmon waxes rhapsodic on cGVHD results as race with Jakafi heats up

6 years ago

ARCH-backed Chinese biotech scores PhIII win for glucokinase-modulating diabetes drug

6 years ago

FDA puts Solid Bio’s lead gene therapy program on hold — again — after another patient is hurt by SGT-001

6 years ago

Voters say Congress needs to curb drug prices. So why do the odds look grim for major legislation this year?

6 years ago

Safety qualms in MyoKardia mid-stage study cause investors to pause

6 years ago

Teva spinout raises $85M in IPO; Novartis beefs up generics unit with $440M deal

6 years ago

Breakthrough status and promise of a speedy review arrives for Opdivo/Yervoy combination as Bristol-Myers bites at ...

6 years ago

FDA to revoke orphan designation for opioid addiction drug Sublocade

6 years ago

Third time unlucky: Lipocine's latest quest to market their oral testosterone drug snubbed again by FDA

6 years ago

Decrying 'arbitrary and capricious' action, RegenxBio sues FDA over clinical holds on gene therapy

6 years ago

The latest Cinderella story in oncology ends with a sudden rout as updated data display spooks investors

6 years ago

Roche's SMA challenge to Biogen's Spinraza franchise looms larger with pivotal win

6 years ago

Roche steers Gazyva into a new PhIII program after combo shows promise in lupus nephritis study

6 years ago

Aslan's latest cancer focus also flops, leaving just two major programs for the troubled biotech

6 years ago

An Israeli biotech gambles on a failed drug, merging with troubled Menlo ahead of PhIII data

6 years ago

Special report: Twenty extraordinary women in biopharma R&D who worked their way to the top

6 years ago

With key test still looming, Celgene and Acceleron nab FDA okay for beta-thalassemia med

6 years ago

AstraZeneca, FibroGen flag appealing pooled safety data on roxa for key segment of the CKD market

6 years ago

First page Previous page 894 895 896897898 899 900 Next page Last page